Doctors reprogram Patients' own cells to attack advanced lung cancer
NCT ID NCT07192900
Summary
This early-stage study is testing the safety of a new personalized immunotherapy for people with advanced cancer that has spread to the lining of the lungs (pleura). Doctors take immune cells from a patient's own lung fluid, grow large numbers of them in a lab, and then infuse them back into the chest cavity along with a drug to help them fight the cancer. The main goal is to see if this process is safe and feasible, and if it might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL EFFUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AHN West Penn Hospital
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.